In Depth 9 Jul 2025
New hope for CIPN: Can emerging therapies ease chemotherapy’s nerve damage?
Delve into the growing field of CIPN, the most common side effect of chemotherapy, as we are getting closer to a first approval.
In Depth
- Latest Posts
In Depth 8 Jul 2025
The biggest biotech funding rounds in June 2025
The companies Insmed, Cidara Therapeutics, and Cogent Biosciences bagged the biggest biotech funding rounds overall in June 2025.
In Depth 7 Jul 2025
Biotech in Vienna: a budding life science hub
As biotech in Vienna raked in €22.7 billion in 2023, there has been a significant increase in innovation, research, and employment in recent years.
In Depth 3 Jul 2025
Revolutionizing glioblastoma treatment: How CAR-T cell therapy could represent a cure for this deadly brain cancer
Find out how CAR-T cell therapy, which has been so groundbreaking in treating blood cancers, could potentially cure glioblastoma.
In Depth 1 Jul 2025
Is an HIV cure possible? The future of HIV therapy
Delve into the field of HIV treatment development. Since the virus was discovered, treatments have improved, but are we close to a cure?
In Depth 27 Jun 2025
Psychedelics sans side effects: neuroplastogens gain ground
The past year has seen several developments in the neuroplastogens field, including Elkedonia’s seed funding to address neuropsychiatric disorders.
ADVERTISEMENT
ADVERTISEMENT
In Depth 25 Jun 2025
ALS: how close are we to a cure?
Let us take a look at how the hunt for amyotrophic lateral sclerosis (ALS) drugs has advanced over the past few years.
In Depth 24 Jun 2025
Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem
Discover what makes Paris’s biotech ecosystem so successful, as it just so happens to be one of the largest biotech clusters in Europe.
In Depth 20 Jun 2025
Stem cell therapy: a potential cure for hearing loss?
As stem cell research gains momentum, researchers are looking at ways to use the therapy to treat hearing loss.
In Depth 18 Jun 2025
From undruggable to oral therapy: The rise of STAT6 degraders
Delve into the STAT6 degrader technology and what it could bring to inflammatory and allergic disease treatment.
In Depth 16 Jun 2025
Did Novo open the Canadian market to GLP-1 generics?
Find out if Novo’s GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a small fee?
In Depth 13 Jun 2025
A new era in migraine treatment: Innovative drugs redefining the field
Discover the new migraine medications, such as monoclonal antibodies and gepants, that are changing migraine treatment for the better.
ADVERTISEMENT
